173 related articles for article (PubMed ID: 31833002)
1. Effect of Androgen Deprivation Therapy on Metabolic Complications and Cardiovascular Risk.
Melloni C; Nelson A
J Cardiovasc Transl Res; 2020 Jun; 13(3):451-462. PubMed ID: 31833002
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular and Metabolic Effects of Androgen-Deprivation Therapy for Prostate Cancer.
Gupta D; Lee Chuy K; Yang JC; Bates M; Lombardo M; Steingart RM
J Oncol Pract; 2018 Oct; 14(10):580-587. PubMed ID: 30312560
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses.
Hu JR; Duncan MS; Morgans AK; Brown JD; Meijers WC; Freiberg MS; Salem JE; Beckman JA; Moslehi JJ
Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):e55-e64. PubMed ID: 31969015
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation therapy: evidence-based management of side effects.
Ahmadi H; Daneshmand S
BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms.
Tivesten Å; Pinthus JH; Clarke N; Duivenvoorden W; Nilsson J
Urol Oncol; 2015 Nov; 33(11):464-75. PubMed ID: 26141678
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure.
Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
Prostate Cancer Prostatic Dis; 2009; 12(3):233-40. PubMed ID: 19488067
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
Grossmann M; Zajac JD
Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation therapy and cardiovascular disease.
Melloni C; Roe MT
Urol Oncol; 2020 Feb; 38(2):45-52. PubMed ID: 30879969
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review.
Collier A; Ghosh S; McGlynn B; Hollins G
Am J Clin Oncol; 2012 Oct; 35(5):504-9. PubMed ID: 21297430
[TBL] [Abstract][Full Text] [Related]
11. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.
Nguyen PL; Je Y; Schutz FA; Hoffman KE; Hu JC; Parekh A; Beckman JA; Choueiri TK
JAMA; 2011 Dec; 306(21):2359-66. PubMed ID: 22147380
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis.
Carneiro A; Sasse AD; Wagner AA; Peixoto G; Kataguiri A; Neto AS; Bianco BA; Chang P; Pompeo AC; Tobias-Machado M
World J Urol; 2015 Sep; 33(9):1281-9. PubMed ID: 25387877
[TBL] [Abstract][Full Text] [Related]
14. [Cardiovascular risks of androgen deprivation therapy for prostate cancer].
Miller K
Urologe A; 2016 May; 55(5):627-31. PubMed ID: 27003571
[TBL] [Abstract][Full Text] [Related]
15. The clinical importance of quantifying body fat distribution during androgen deprivation therapy for prostate cancer.
Foulkes SJ; Daly RM; Fraser SF
Endocr Relat Cancer; 2017 Mar; 24(3):R35-R48. PubMed ID: 28062546
[TBL] [Abstract][Full Text] [Related]
16. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.
Taylor LG; Canfield SE; Du XL
Cancer; 2009 Jun; 115(11):2388-99. PubMed ID: 19399748
[TBL] [Abstract][Full Text] [Related]
17. Metabolic and cardiovascular effects of androgen deprivation therapy.
Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy.
Saylor PJ; Keating NL; Smith MR
J Gen Intern Med; 2009 Nov; 24 Suppl 2(Suppl 2):S389-94. PubMed ID: 19838837
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer: cardiovascular mortality and androgen deprivation.
Basaria S
Nat Rev Urol; 2009 May; 6(5):252-3. PubMed ID: 19424172
[TBL] [Abstract][Full Text] [Related]
20. ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury.
Crawford ED; Moul JW
Oncology (Williston Park); 2015 Jan; 29(1):55-8, 65-6. PubMed ID: 25592210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
